Colloidal silver against macrophage infections and biofilms of atypical mycobacteria

Biometals. 2023 Aug;36(4):913-925. doi: 10.1007/s10534-023-00494-w. Epub 2023 Feb 2.

Abstract

Skin and soft tissue infection (SSTI) caused by atypical mycobacteria such as Mycobacterium abscessus and Mycobacterium avium intracellulare complex (MAIC) have increased in recent years. Current therapeutic options are limited, and hence new and better therapies are urgently required. Colloidal Silver (CS) has been identified for its widespread antibacterial properties and silver-impregnated dressings have been used for SSTIs caused by various pathogens. The efficacy of Green Synthesized Colloidal Silver (GSCS) was investigated for bacterial growth inhibition (BGI) using a microdilution method and minimum biofilm eradication concentration (MBEC) using resazurin assay and confocal scanning laser microscopy (CSLM) of M. abscessus (n = 5) and MAIC (n = 5). The antibacterial effect of GSCS against M. abscessus infected macrophages was also evaluated. The in vitro cytotoxicity of GSCS on a human keratinocyte cell line (HaCaT) and neonatal foreskin fibroblasts was analyzed by the crystal violet proliferation assay. Average BGI and MBEC of GSCS varied between 0.7 and 22 ppm for M. abscessus and MAIC. The concentration of 3 ppm reduced M. abscessus-infection in macrophages significantly. GSCS was not cytotoxic to HaCaT and neonatal foreskin fibroblast cells at concentrations < 3 ppm up to 2 h exposure time. GSCS therefore, has the potential for topical application against atypical mycobacterial SSTI.

Keywords: Atypical mycobacteria; Colloidal silver; Green synthesis; Macrophages; Skin infection.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Biofilms
  • Humans
  • Infant, Newborn
  • Macrophages
  • Nontuberculous Mycobacteria* / physiology
  • Silver* / pharmacology

Substances

  • colloidal silver
  • Silver
  • Anti-Bacterial Agents